NCT06300463View on ClinicalTrials.gov

Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases

PHASE2RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

March 26, 2024

Primary Completion Date

September 30, 2026

Study Completion Date

March 31, 2027

Conditions
Colorectal Cancer MetastaticLiver MetastasesColorectal Cancer
Interventions
DRUG

Botensilimab

75 mg IV Q6W

DRUG

Balstilimab

450 mg IV Q3W

DRUG

AGEN1423

30 mg/kg IV Q3W

RADIATION

Radiation

8Gy x 3 between Day 0 - 18; Allowed techniques for radiation are 3D conformal, intensity modulated radiotherapy (IMRT), or SBRT

Trial Locations (1)

10065

RECRUITING

Weill Cornell Medicine/NewYork-Presbyterian Hospital, New York

Sponsors

Collaborators (1)

Agenus Inc.
All Listed Sponsors
collaborator

Agenus Inc.

INDUSTRY

lead

Weill Medical College of Cornell University

OTHER